Multiple case reports and series have described therapeutic responses to BRAF-targeted therapy in BRAF V600E-mutated gliomas across all WHO tumor grades in both pediatric and adult populations, including some cases of complete tumor regression (2–5). The gene discussed is BRAF; the disease is central nervous system cancer.